Last fall, a new season began with a crucial difference: for the first time, doctors had tools to protect the youngest babies from RSV. Parents could either get a new antibody shot for their infant after birth or get vaccinated themselves during pregnancy to pass on protection. A new report takes a first look at how many infants born from October 2023 through March 2024 in the United States received one of these forms of immunization. The report does not share the actual coverage numbers, safety information, or how well the protection worked. It simply marks the start of tracking this important public health effort. Since this is an early observational report, it doesn't tell us why some families might have gotten the protection and others didn't, or what the barriers to access might be. It's a starting point for understanding how these new tools are being used to guard babies against a serious virus.
RSV Immunization Coverage Among US Infants Receiving Nirsevimab or Maternal VaccinationHow many infants are getting new RSV protection? A first look
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This observational report describes respiratory syncytial virus (RSV) immunization coverage among infants born in the United States from October 2023 through March 2024. The population included infants who received the nirsevimab monoclonal antibody or whose mothers received RSV vaccination during pregnancy. The study design was descriptive, and no comparator group was specified.
The report does not provide the sample size, specific coverage rates, absolute numbers, or statistical measures for the main outcome of RSV immunization coverage. No data on secondary outcomes, follow-up duration, or safety and tolerability of the interventions were reported. Adverse events, serious adverse events, and discontinuation rates were not described.
Key limitations include the absence of reported results, which prevents assessment of the actual immunization coverage achieved in this population. The lack of comparative data, safety information, and details on study methodology restricts interpretation. Funding sources and potential conflicts of interest were not reported.
For clinical practice, this report serves only as a preliminary acknowledgment that RSV immunization via these methods was being monitored in the specified US infant cohort during the 2023-2024 season. The absence of reported coverage rates means no conclusions can be drawn about the effectiveness or reach of these immunization strategies. Clinicians should await studies with complete outcome reporting to inform practice.
More on Respiratory Syncytial Virus Infection
View Original Abstract ↓
Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma
New Asthma Drug Cuts Attacks Without Recent Crisis
Related in Allergy & Immunology
From Other Specialties
